Skip to main content

Advertisement

SpringerLink
Log in

Toward personalized management in bladder cancer: the promise of novel molecular taxonomy

  • Invited Annual Review Issue
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Empowered by the recent advances in next generation sequencing and bioinformatics technology, an unprecedented wave of integrated transcriptomic and genomic studies have impacted the field of bladder cancer. These studies not only have confirmed previously charted genetic pathways in bladder cancer development but also have led to the discovery of numerous additional crucial driver genetic alterations. As a result, a novel genomic-based taxonomy is emerging that promises to better define clinically relevant intrinsic subtypes of bladder cancer. The current review is an update on the above advances and their significant implications on the future of bladder cancer patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2016) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol

  2. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T et al (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73(24):7162–7167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mitra AP (2016) Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol 8(3):215–233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Netto GJ, Tafe LJ (2016) Emerging bladder cancer biomarkers and targets of therapy. Urol Clin North Am 43(1):63–76

    Article  PubMed  Google Scholar 

  5. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680–684

    Article  PubMed  Google Scholar 

  6. Dinney CPN, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L et al (2004) Focus on bladder cancer. Cancer Cell 6(2):111–116

    Article  CAS  PubMed  Google Scholar 

  7. Wu X-R (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5(9):713–725

    Article  CAS  PubMed  Google Scholar 

  8. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W et al (2016) Bladder cancer. Lancet Lond Engl

  9. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S et al (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43(9):875–878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G et al (2015) Invasive bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res Off J Am Assoc Cancer Res. 21(20):4514–4524

    Article  CAS  Google Scholar 

  11. Solomon DA, Kim J-S, Bondaruk J, Shariat SF, Wang Z-F, Elkahloun AG et al (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45(12):1428–1430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Márquez M, Vazquez M et al (2013) Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45(12):1464–1469

    Article  PubMed  PubMed Central  Google Scholar 

  13. Höglund M (2007) On the origin of syn- and metachronous urothelial carcinomas. Eur Urol 51(5):1185–1193

    Article  PubMed  Google Scholar 

  14. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC (2000) Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9(20):2973–2980

    Article  PubMed  Google Scholar 

  15. Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H et al (2014) Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 7(5):1649–1663

    Article  CAS  PubMed  Google Scholar 

  16. Lamy P, Nordentoft I, Birkenkamp-Demtröder K, Thomsen MBH, Villesen P, Vang S et al (2016) Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res 76(19):5894–5906

    Article  CAS  PubMed  Google Scholar 

  17. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6(9):678–686

    Article  CAS  PubMed  Google Scholar 

  18. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP et al (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 22(6):1007–1013

    Article  CAS  Google Scholar 

  19. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177(2):481–487 discussion 487

    Article  PubMed  Google Scholar 

  20. van Rhijn BWG, Zuiverloon TCM, Vis AN, Radvanyi F, van Leenders GJLH, Ooms BCM et al (2010) Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 58(3):433–441

    Article  PubMed  Google Scholar 

  21. van Rhijn BWG, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms ECM et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol Off J Am Soc Clin Oncol 21(10):1912–1921

    Article  Google Scholar 

  22. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R et al (2006) Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 59(1):83–88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U et al (2009) Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 101(2):114–119

    Article  PubMed  Google Scholar 

  24. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC et al (2004) Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45(5):606–612

    Article  CAS  PubMed  Google Scholar 

  25. Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN et al (2015) Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol 67(2):198–201

    Article  PubMed  Google Scholar 

  26. di Martino E, Tomlinson DC, Knowles MA (2012) A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012:429213

    Article  PubMed  PubMed Central  Google Scholar 

  27. van Rhijn BWG, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN et al (2012) The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 187(1):310–314

    PubMed  Google Scholar 

  28. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):465–477

    Article  Google Scholar 

  29. Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N et al (2005) Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 23(13):2903–2910

    Article  CAS  Google Scholar 

  30. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA et al (2007) Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 13(7):2046–2053

    Article  CAS  Google Scholar 

  31. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, et al (2012) Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7(6)

  32. Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G et al (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70(9):3463–3472

    Article  CAS  PubMed  Google Scholar 

  33. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152–165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111(8):3110–3115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315–322

    Article  Google Scholar 

  36. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CPN (2015) Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 29(2):377–394

    Article  PubMed  Google Scholar 

  37. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A et al (2016) Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12:105–117

    Article  PubMed  PubMed Central  Google Scholar 

  38. Dyrskjøt L, Thykjaer T, Kruhøffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S et al (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33(1):90–96

    Article  PubMed  Google Scholar 

  39. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64(11):4040–4048

    Article  PubMed  Google Scholar 

  40. Dyrskjøt L, Zieger K, Kruhøffer M, Thykjaer T, Jensen JL, Primdahl H et al (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 11(11):4029–4036

    Article  Google Scholar 

  41. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C et al (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res Off J Am Assoc Cancer Res. 13(12):3545–3551

    Article  Google Scholar 

  42. Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C et al (2014) Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep 9(4):1235–1245

    Article  CAS  PubMed  Google Scholar 

  43. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70

    Article  Google Scholar 

  44. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525

    Article  Google Scholar 

  45. Ho PL, Kurtova A, Chan KS (2012) Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 9(10):583–594

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. McConkey DJ, Choi W, Dinney CPN (2015) Genetic subtypes of invasive bladder cancer. Curr Opin Urol 25(5):449–458

    Article  PubMed  Google Scholar 

  47. Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30(1):27–42

    Article  CAS  PubMed  Google Scholar 

  48. Lerner SP, DJ MC, Hoadley KA, Chan KS, Kim WY, Radvanyi F et al (2016) Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2(1):37–47

    Article  PubMed  PubMed Central  Google Scholar 

  49. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ (2015) Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 41(2):170–178

    Article  CAS  PubMed  Google Scholar 

  50. Montironi R, Santoni M, Lopez-Beltran A, Cheng L, Moch H, Scarpelli M (2015) Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. Curr Drug Targets 16(2):96–102

    Article  CAS  PubMed  Google Scholar 

  51. Gartrell BA, Sonpavde G (2013) Emerging drugs for urothelial carcinoma. Expert Opin Emerg Drugs 18(4):477–494

    Article  CAS  PubMed  Google Scholar 

  52. Bellmunt J, Teh BT, Tortora G, Rosenberg JE (2013) Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol 10(10):557–570

    Article  CAS  PubMed  Google Scholar 

  53. Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A et al (2013) Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol 44(9):1766–1772

    Article  CAS  PubMed  Google Scholar 

  54. Chaux A, Compérat E, Varinot J, Hicks J, Lecksell K, Solus J et al (2013) High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection. Urology 81(1):116–122

    Article  PubMed  Google Scholar 

  55. Gonzalez-Roibon ND, Chaux A, Al-Hussain T, Osunkoya AO, Bezerra SM, Hicks J et al (2013) Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. Hum Pathol 44(4):612–622

    Article  CAS  PubMed  Google Scholar 

  56. Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM et al (2011) Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 35(10):1549–1556

    Article  PubMed  PubMed Central  Google Scholar 

  57. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562

    Article  CAS  PubMed  Google Scholar 

  58. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Fedorov O, Lingard H, Wells C, Monteiro OP, Picaud S, Keates T et al (2014) [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J Med Chem 57(2):462–476

    Article  CAS  PubMed  Google Scholar 

  60. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136(26):9308–9319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM (2015) The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol 193(1):19–29

    Article  CAS  PubMed  Google Scholar 

  62. Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S et al (2015) Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J Urol 194(4):1120–1131

    Article  CAS  PubMed  Google Scholar 

  63. Bajorin DF, Sharma P, Quinn DI, Plimack ER, Hoffman-Censits JH, O’Donnell PH, et al (2016) Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). J Clin Oncol 34(4513)

  64. Richards DA, Braiteh FS, Garcia AA, Denlinger CS, Conkling PR, Edenfield WJ et al (2014) A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. J Clin Oncol 32(651):5

    Google Scholar 

  65. Hussain MHA, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol Off J Am Soc Clin Oncol 25(16):2218–2224

    Article  CAS  Google Scholar 

  66. Hansel DE, Swain E, Dreicer R, Tubbs RR (2008) HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 130(2):274–281

    Article  PubMed  Google Scholar 

  67. Dees EC, Infante JR, Cohen RB, O’Neil BH, Jones S, von Mehren M et al (2011) Phase 1 study of MLN8054, a selective inhibitor of aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67(4):945–954

    Article  CAS  PubMed  Google Scholar 

  68. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K et al (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res Off J Am Assoc Cancer Res 18(17):4775–4784

    Article  CAS  Google Scholar 

  69. Lin C-C, Su W-C, Yen C-J, Hsu C-H, Su W-P, Yeh K-H et al (2014) A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 110(10):2434–2440

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Thomsen MBH, Nordentoft I, Lamy P, Høyer S, Vang S, Hedegaard J et al (2016) Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Mol Oncol 10(9):1450–1460

    Article  PubMed  PubMed Central  Google Scholar 

  71. Dinney CPN, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R et al (2014) Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute forum. Urol Oncol 32(8):1108–1115

    Article  PubMed  PubMed Central  Google Scholar 

  72. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC et al (2015) Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 67(2):241–249

    Article  PubMed  Google Scholar 

  73. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866

    Article  CAS  PubMed  Google Scholar 

  74. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol Off J Am Soc Clin Oncol 29(16):2171–2177

    Article  Google Scholar 

  75. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68(6):959–967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Xylinas E, Hassler MR, Zhuang D, Krzywinski M, Erdem Z, Robinson BD, et al (2016) An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. Biomolecules 6(3)

  77. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl. 387(10031):1909–1920

    Article  CAS  Google Scholar 

  78. Netto GJ (2016) Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet Lond Engl 387(10031):1881–1882

    Article  Google Scholar 

  79. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 17

  80. Mitra AP, Cote RJ (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4:251–285

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Alabama in Birmingham (UAB), Birmingham, AL, USA

    Marie-Lisa Eich & George J. Netto

  2. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

    Lars Dyrskjøt

Authors
  1. Marie-Lisa Eich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars Dyrskjøt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George J. Netto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George J. Netto.

Ethics declarations

The authors adhere to institutional ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

The authors received no funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eich, ML., Dyrskjøt, L. & Netto, G.J. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch 471, 271–280 (2017). https://doi.org/10.1007/s00428-017-2119-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2119-x

Keywords

Search

Navigation